Patrick Flume to Treatment Outcome
This is a "connection" page, showing publications Patrick Flume has written about Treatment Outcome.
Connection Strength
0.787
-
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 07; 9(7):733-746.
Score: 0.079
-
Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):737-742.
Score: 0.068
-
Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):809-815.
Score: 0.057
-
Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax. 2016 Mar; 71(3):223-9.
Score: 0.053
-
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015 Jul; 14(4):507-14.
Score: 0.052
-
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep; 142(3):718-724.
Score: 0.044
-
Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respir Med. 2011 Dec; 105 Suppl 2:S18-23.
Score: 0.042
-
Airway-clearance therapy guidelines and implementation. Respir Care. 2009 Jun; 54(6):733-50; discussion 751-3.
Score: 0.035
-
Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion. BMC Infect Dis. 2022 Mar 12; 22(1):246.
Score: 0.021
-
Treatment options for cystic fibrosis: case study and panel discussion. Pharmacotherapy. 2002 Mar; 22(3 Pt 2):86S-87S.
Score: 0.021
-
Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial. Ann Am Thorac Soc. 2021 07; 18(7):1147-1157.
Score: 0.020
-
Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure. Chest. 2021 09; 160(3):831-842.
Score: 0.020
-
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. J Cyst Fibros. 2021 01; 20(1):78-85.
Score: 0.019
-
Is bronchiectasis really a disease? Eur Respir Rev. 2020 Mar 31; 29(155).
Score: 0.018
-
Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. J Cyst Fibros. 2020 05; 19(3):370-375.
Score: 0.018
-
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):708-713.
Score: 0.018
-
Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. J Cyst Fibros. 2019 03; 18(2):236-243.
Score: 0.017
-
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018 12 15; 198(12):1559-1569.
Score: 0.017
-
Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am J Respir Crit Care Med. 2017 03 15; 195(6):814-823.
Score: 0.015
-
Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May; 16(3):371-379.
Score: 0.015
-
The challenges of maintaining momentum in CF drug development and approval - Commentary. J Cyst Fibros. 2017 03; 16(2):170-171.
Score: 0.015
-
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. J Cyst Fibros. 2016 09; 15(5):634-40.
Score: 0.014
-
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros. 2016 07; 15(4):495-502.
Score: 0.014
-
One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2016 Apr; 51(4):372-8.
Score: 0.014
-
Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):227-33.
Score: 0.013
-
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015 Jul; 3(7):524-33.
Score: 0.013
-
Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med. 1994 Jun; 149(6):1601-7.
Score: 0.012
-
Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012 Mar 15; 185(6):645-52.
Score: 0.010
-
Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? Respir Med. 2011 Dec; 105 Suppl 2:S9-17.
Score: 0.010
-
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011 Jun 01; 183(11):1510-6.
Score: 0.010
-
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011 Jan; 10(1):54-61.
Score: 0.010
-
Effect of pulmonary rehabilitation on quality of life in patients with COPD: the use of SF-36 summary scores as outcomes measures. J Cardiopulm Rehabil. 2000 Jul-Aug; 20(4):231-4.
Score: 0.005